BR112023001575A2 - Método in vitro ou ex vivo para diagnóstico ou prognóstico de doença neurodegenerativa e uso de um kit diagnóstico para implementação do mesmo - Google Patents

Método in vitro ou ex vivo para diagnóstico ou prognóstico de doença neurodegenerativa e uso de um kit diagnóstico para implementação do mesmo

Info

Publication number
BR112023001575A2
BR112023001575A2 BR112023001575A BR112023001575A BR112023001575A2 BR 112023001575 A2 BR112023001575 A2 BR 112023001575A2 BR 112023001575 A BR112023001575 A BR 112023001575A BR 112023001575 A BR112023001575 A BR 112023001575A BR 112023001575 A2 BR112023001575 A2 BR 112023001575A2
Authority
BR
Brazil
Prior art keywords
neurodegenerative disease
prognosis
diagnosis
disease
vitro
Prior art date
Application number
BR112023001575A
Other languages
English (en)
Inventor
Piccirella Simona
Letizia Uberti Daniela
Original Assignee
Diadem S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT102020000018544A external-priority patent/IT202000018544A1/it
Application filed by Diadem S P A filed Critical Diadem S P A
Publication of BR112023001575A2 publication Critical patent/BR112023001575A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/36—Post-translational modifications [PTMs] in chemical analysis of biological material addition of addition of other proteins or peptides, e.g. SUMOylation, ubiquitination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MÉTODO IN VITRO OU EX VIVO PARA DIAGNÓSTICO OU PROGNÓSTICO DE DOENÇA NEURODEGENERATIVA E USO DE UM KIT DIAGNÓSTICO PARA IMPLEMENTAÇÃO DO MESMO. A presente invenção refere-se à sequência e modificações póstradução (PTMs) de p53 e ao seu uso como biomarcadores no diagnóstico de doença neurodegenerativa e declínio cognitivo e/ou no prognóstico da doença de Alzheimer em diferentes estágios e/ou de doença neurodegenerativa em uma amostra biológica. A invenção também provê um1) método de diagnóstico baseado em uma análise de espectrometria de massa altamente precisa para o diagnóstico de doença neurodegenerativa, incluindo comprometimento cognitivo leve (MCI), doença de Alzheimer (AD),demência fronto-temporal (FTD), corpos de Lewi (LB) e demência vascular (VD) em um sujeito, avaliando as PTMs para a referida proteína de sequência linear p53 e possível corte de sua sequência completa especificamente no plasma humano de pacientes; e 2) prognóstico de AD em pacientes com CU e MCI.
BR112023001575A 2020-07-30 2021-07-27 Método in vitro ou ex vivo para diagnóstico ou prognóstico de doença neurodegenerativa e uso de um kit diagnóstico para implementação do mesmo BR112023001575A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102020000018544A IT202000018544A1 (it) 2020-07-30 2020-07-30 Modificazioni post-traslazionali su p-53 quali marcatori nella diagnosi e prognosi di malattia neurodegenerativa
PCT/IB2021/056792 WO2022023964A1 (en) 2020-07-30 2021-07-27 P53 post-translational modifications as markers in the diagnosis and prognosis of a neurodegenerative disease

Publications (1)

Publication Number Publication Date
BR112023001575A2 true BR112023001575A2 (pt) 2023-04-04

Family

ID=80004247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001575A BR112023001575A2 (pt) 2020-07-30 2021-07-27 Método in vitro ou ex vivo para diagnóstico ou prognóstico de doença neurodegenerativa e uso de um kit diagnóstico para implementação do mesmo

Country Status (10)

Country Link
US (2) US20240230678A1 (pt)
EP (1) EP4189398A1 (pt)
JP (1) JP2023536162A (pt)
KR (1) KR20230042506A (pt)
CN (1) CN116235055A (pt)
AU (1) AU2021317020A1 (pt)
BR (1) BR112023001575A2 (pt)
CA (1) CA3190285A1 (pt)
IL (1) IL300267A (pt)
ZA (1) ZA202301286B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024148357A2 (en) * 2023-01-08 2024-07-11 Diadem Spa U-p53 peptides as markers in the rate of progression of cognitive decline to alzheimer's disease

Also Published As

Publication number Publication date
US20220034912A1 (en) 2022-02-03
CA3190285A1 (en) 2022-02-03
US20240230678A1 (en) 2024-07-11
AU2021317020A1 (en) 2023-03-02
ZA202301286B (en) 2023-02-22
IL300267A (en) 2023-03-01
KR20230042506A (ko) 2023-03-28
JP2023536162A (ja) 2023-08-23
CN116235055A (zh) 2023-06-06
EP4189398A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
Lee et al. The search for a peripheral biopsy indicator of α-synuclein pathology for Parkinson disease
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
Cohen et al. The psychiatric symptomatology of deficit schizophrenia: a meta-analysis
BRPI0509419A (pt) método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
BR112012025870A2 (pt) uso de pelo menos uma razão quantitativa de dois diferentes peptídeos beta-amiloides, metodos e kit para determinar a probabilidade de um paciente contrair a doença de alzheimer (ad)
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
Caruso et al. Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies
CY1110948T1 (el) Μεθοδος διαγνωσης lawsonia intracellularis
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
BR112023001575A2 (pt) Método in vitro ou ex vivo para diagnóstico ou prognóstico de doença neurodegenerativa e uso de um kit diagnóstico para implementação do mesmo
BR112022000755A2 (pt) Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento
Postupna et al. Cerebral cortical Aβ 42 and PHF-τ in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE
Poudel-Tandukar et al. Serum albumin levels and depression in people living with human immunodeficiency virus infection: a cross-sectional study
Ayromlou et al. Electrodiagnostic evaluation of peripheral nervous system changes in patients with multiple sclerosis
Debono et al. Is the incidence of elbow osteoarthritis underestimated? Insights from paleopathology
AR058510A1 (es) Procedimiento de diagnostico de enfermedades hepaticas y de muestreo de moleculas para el tratamiento de estas enfermedades
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
JP2008107275A (ja) アレルギー性皮膚炎の診断法
BR112022022045A2 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento
KR102016385B1 (ko) Gaba를 바이오마커로 이용한 결핵 진단을 위한 정보 제공 방법
Rattan et al. Role of contact allergens in chronicity and relapses of nummular eczema
Kapila Metabolomics and oral disease diagnosis
PV et al. Phase-0: A General Overview
Pilotto et al. Differences between plasma and CSF p-tau181 and p-tau231 in early Alzheimer’s disease